American Association for Cancer Research

sorry, we can't preview this file

23266066cir180647-sup-208685_2_supp_5275917_pm5hg8.docx (9.1 MB)

Supplementary Figures and Tables from Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

Download (9.1 MB)
journal contribution
posted on 2023-04-04, 00:44 authored by Biagio Di Lorenzo, André E. Simões, Francisco Caiado, Paola Tieppo, Daniel V. Correia, Tânia Carvalho, Maria Gomes da Silva, Julie Déchanet-Merville, Ton N. Schumacher, Immo Prinz, Haakan Norell, Sarina Ravens, David Vermijlen, Bruno Silva-Santos

Supplementary Figures 1-5 and tables 1-3


Fundação para a Ciência e Tecnologia





Acute myeloid leukemia (AML) remains a clinical challenge due to frequent chemotherapy resistance and deadly relapses. We are exploring the immunotherapeutic potential of peripheral blood Vδ1+ T cells, which associate with improved long-term survival of stem-cell transplant recipients but have not yet been applied as adoptive cell therapy. Using our clinical-grade protocol for expansion and differentiation of “Delta One T” (DOT) cells, we found DOT cells to be highly cytotoxic against AML primary samples and cell lines, including cells selected for resistance to standard chemotherapy. Unlike chemotherapy, DOT-cell targeting did not select for outgrowth of specific AML lineages, suggesting a broad recognition domain, an outcome that was consistent with the polyclonality of the DOT-cell T-cell receptor (TCR) repertoire. However, AML reactivity was only slightly impaired upon Vδ1+ TCR antibody blockade, whereas it was strongly dependent on expression of the NKp30 ligand, B7-H6. In contrast, DOT cells did not show reactivity against normal leukocytes, including CD33+ or CD123+ myeloid cells. Adoptive transfer of DOT cells in vivo reduced AML load in the blood and target organs of multiple human AML xenograft models and significantly prolonged host survival without detectable toxicity, thus providing proof-of-concept for DOT-cell application in AML treatment.

Usage metrics

    Cancer Immunology Research



    Ref. manager